Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.

Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ.

Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685. doi: 10.1016/S2468-1253(19)30198-0. Epub 2019 Jul 17.

PMID:
31326345
2.

Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC.

Lancet HIV. 2019 Aug;6(8):e498-e508. doi: 10.1016/S2352-3018(19)30145-6. Epub 2019 Jul 15.

PMID:
31320290
3.

Impact of Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Dual Infection on Female Genital Tract Mucosal Immunity and the Vaginal Microbiome.

Keller MJ, Huber A, Espinoza L, Serrano MG, Parikh HI, Buck GA, Gold JA, Wu Y, Wang T, Herold BC.

J Infect Dis. 2019 Jul 31;220(5):852-861. doi: 10.1093/infdis/jiz203.

PMID:
31111902
4.

Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection.

Murphy K, Keller MJ, Anastos K, Sinclair S, Devlin JC, Shi Q, Hoover DR, Starkman B, McGillick J, Mullis C, Minkoff H, Dominguez-Bello MG, Herold BC.

PLoS One. 2019 Apr 26;14(4):e0216049. doi: 10.1371/journal.pone.0216049. eCollection 2019.

5.

The direct and indirect effects of motor competence on adolescents' mental health through health-related physical fitness.

Gu X, Zhang T, Chu TLA, Keller MJ, Zhang X.

J Sports Sci. 2019 Sep;37(17):1927-1933. doi: 10.1080/02640414.2019.1605652. Epub 2019 Apr 15.

PMID:
30982466
6.

Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer.

Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Anastos K, Xie X, Minkoff H, Xue X, Reimers LL, Kuniholm M, DʼSouza G, Colie C, Aouizerat B, Palefsky JM, Strickler HD.

AIDS. 2018 Nov 28;32(18):2821-2826. doi: 10.1097/QAD.0000000000002005.

PMID:
30234608
7.

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.

Taneva E, Sinclair S, Mesquita PM, Weinrick B, Cameron SA, Cheshenko N, Reagle K, Frank B, Srinivasan S, Fredricks D, Keller MJ, Herold BC.

JCI Insight. 2018 Jul 12;3(13). pii: 99545. doi: 10.1172/jci.insight.99545.

8.

Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.

Watnick D, Keller MJ, Stein K, Bauman LJ.

AIDS Behav. 2018 Feb;22(2):421-436. doi: 10.1007/s10461-017-1962-8.

PMID:
29147810
9.

The roles of physical activity and sedentary behavior on Hispanic children's mental health: a motor skill perspective.

Gu X, Keller MJ, Weiller-Abels KH, Zhang T.

Qual Life Res. 2018 Jan;27(1):185-193. doi: 10.1007/s11136-017-1687-1. Epub 2017 Aug 16.

PMID:
28815374
10.

Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach.

Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H, Keller MJ, Fischl M, Palefsky J, Flowers L, Rahangdale L, Milam J, Shrestha S, Colie C, DʼSouza G.

AIDS. 2017 Apr 24;31(7):1035-1044. doi: 10.1097/QAD.0000000000001450.

11.

Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Mesquita PMM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC.

J Infect Dis. 2017 Feb 15;215(4):614-622. doi: 10.1093/infdis/jiw612.

12.

In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.

Novetsky AP, Keller MJ, Gradissimo A, Chen Z, Morgan SL, Xue X, Strickler HD, Fernández-Romero JA, Burk R, Einstein MH.

Gynecol Oncol. 2016 Nov;143(2):313-318. doi: 10.1016/j.ygyno.2016.09.003. Epub 2016 Sep 10.

13.

Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.

Keller MJ, McGinn AP, Lo Y, Huber A, Espinoza L, Minkoff H, Colie C, Nowicki MJ, D'Souza G, Anastos K.

Am J Reprod Immunol. 2016 Jun;75(6):631-42. doi: 10.1111/aji.12518. Epub 2016 May 5.

14.

Corrigendum to "Calcium release-activated calcium (CRAC) channels mediate the β2 -adrenergic regulation of Na,K-ATPase" [FEBS Lett. 588 (24) (2014) 4686-4693].

Keller MJ, Lecuona E, Prakriya M, Cheng Y, Soberanes S, Scott Budinger GR, Sznajder JI.

FEBS Lett. 2015 Jan 30;589(3):414. doi: 10.1016/j.febslet.2014.12.017. No abstract available.

15.
16.

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.

Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.

AIDS. 2016 Mar 13;30(5):743-51. doi: 10.1097/QAD.0000000000000979.

17.

Loss of Innate Host Defense Following Unprotected Vaginal Sex.

Nakra NA, Madan RP, Buckley N, Huber AM, Freiermuth JL, Espinoza L, Walsh J, Parikh UM, Penrose KJ, Keller MJ, Herold BC.

J Infect Dis. 2016 Mar 1;213(5):840-7. doi: 10.1093/infdis/jiv488. Epub 2015 Oct 13.

18.

Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.

Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Castle PE, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Fischl MA, Palefsky JM, Strickler HD.

Clin Infect Dis. 2015 Nov 15;61(10):1573-81. doi: 10.1093/cid/civ569. Epub 2015 Jul 17.

19.

Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.

Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, Augenbraun MH, Gange SJ, Liu C, Mack WJ, Gandhi M; Women’s Interagency HIV Study (WIHS).

PLoS One. 2015 Jun 8;10(6):e0129100. doi: 10.1371/journal.pone.0129100. eCollection 2015.

20.

Plasmodium falciparum Infection Does Not Affect Human Immunodeficiency Virus Viral Load in Coinfected Rwandan Adults.

Subramaniam K, Plank RM, Lin N, Goldman-Yassen A, Ivan E, Becerril C, Kemal K, Heo M, Keller MJ, Mutimura E, Anastos K, Daily JP.

Open Forum Infect Dis. 2014 Aug 21;1(2):ofu066. doi: 10.1093/ofid/ofu066. eCollection 2014 Sep.

21.

Calcium release-activated calcium (CRAC) channels mediate the β(2)-adrenergic regulation of Na,K-ATPase.

Keller MJ, Lecuona E, Prakriya M, Cheng Y, Soberanes S, Budinger GR, Sznajder JI.

FEBS Lett. 2014 Dec 20;588(24):4686-93. doi: 10.1016/j.febslet.2014.10.041. Epub 2014 Nov 11. Erratum in: FEBS Lett. 2015 Jan 30;589(3):414.

22.

TLR7 induces anergy in human CD4(+) T cells.

Dominguez-Villar M, Gautron AS, de Marcken M, Keller MJ, Hafler DA.

Nat Immunol. 2015 Jan;16(1):118-28. doi: 10.1038/ni.3036. Epub 2014 Nov 17.

23.

Long-term cumulative detection of human papillomavirus among HIV seropositive women.

Massad LS, Xie X, Burk R, Keller MJ, Minkoff H, DʼSouza G, Watts DH, Palefsky J, Young M, Levine AM, Cohen M, Strickler HD.

AIDS. 2014 Nov 13;28(17):2601-8. doi: 10.1097/QAD.0000000000000455.

24.

Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.

Ursell LK, Gunawardana M, Chang S, Mullen M, Moss JA, Herold BC, Keller MJ, McDonald D, González A, Knight R, Baum MM.

Antiviral Res. 2014 Feb;102:87-94. doi: 10.1016/j.antiviral.2013.12.004. Epub 2013 Dec 19.

25.

Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials.

van der Straten A, Cheng H, Mensch B, Friedland B, Katzen L, Littlefield S, Buckley N, Espinoza L, Keller MJ, Herold BC, Einstein MH.

Sex Transm Dis. 2013 Dec;40(12):950-6. doi: 10.1097/OLQ.0000000000000053.

26.

Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex.

Keller MJ, Buckley N, Katzen LL, Walsh J, Friedland B, Littlefield S, Lin J, Xue X, Cornelison T, Herold BC, Einstein MH.

Sex Transm Dis. 2013 Dec;40(12):939-43. doi: 10.1097/OLQ.0000000000000040.

27.

Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.

Herold BC, Keller MJ, Shi Q, Hoover DR, Carpenter CA, Huber A, Parikh UM, Agnew KJ, Minkoff H, Colie C, Nowicki MJ, DʼSouza G, Watts DH, Anastos K.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):485-93. doi: 10.1097/QAI.0b013e3182961cfc.

28.

Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions.

Kalyoussef S, Nieves E, Dinerman E, Carpenter C, Shankar V, Oh J, Burd B, Angeletti RH, Buckheit KW, Fredricks DN, Madan RP, Keller MJ, Herold BC.

PLoS One. 2012;7(11):e49506. doi: 10.1371/journal.pone.0049506. Epub 2012 Nov 19.

29.

Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.

Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, Fredricks DN, Herold BC.

PLoS One. 2012;7(10):e46901. doi: 10.1371/journal.pone.0046901. Epub 2012 Oct 8.

30.

Trends in contraceptive use among women with human immunodeficiency virus.

Sun M, Peipert JF, Zhao Q, Wilson TE, Weber KM, Sanchez-Keeland L, DʼSouza G, Young M, Watts DH, Keller MJ, Cohan D, Massad LS.

Obstet Gynecol. 2012 Oct;120(4):783-90.

31.

Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study.

Sharma A, Tian F, Yin MT, Keller MJ, Cohen M, Tien PC.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):469-76. doi: 10.1097/QAI.0b013e31826cba6c.

32.

Changes in the soluble mucosal immune environment during genital herpes outbreaks.

Keller MJ, Madan RP, Shust G, Carpenter CA, Torres NM, Cho S, Khine H, Huang ML, Corey L, Kim M, Herold BC.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):194-202.

33.

Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.

Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts DH, Levine AM, Castle PE, Colie C, Palefsky JM, Strickler HD.

JAMA. 2012 Jul 25;308(4):362-9. doi: 10.1001/jama.2012.5664.

34.

Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents.

Madan RP, Carpenter C, Fiedler T, Kalyoussef S, McAndrew TC, Viswanathan S, Kim M, Keller MJ, Fredricks DN, Herold BC.

PLoS One. 2012;7(7):e40415. doi: 10.1371/journal.pone.0040415. Epub 2012 Jul 10.

35.

Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring.

Keller MJ, Malone AM, Carpenter CA, Lo Y, Huang M, Corey L, Willis R, Nguyen C, Kennedy S, Gunawardana M, Guerrero D, Moss JA, Baum MM, Smith TJ, Herold BC.

J Antimicrob Chemother. 2012 Aug;67(8):2005-12. doi: 10.1093/jac/dks151. Epub 2012 May 3.

36.

Topical prophylaxis for HIV prevention in women: becoming a reality.

Verma NA, Lee AC, Herold BC, Keller MJ.

Curr HIV/AIDS Rep. 2011 Jun;8(2):104-13. doi: 10.1007/s11904-011-0075-7.

37.

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC.

PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.

38.

Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.

Herold BC, Mesquita PM, Madan RP, Keller MJ.

Am J Reprod Immunol. 2011 Mar;65(3):325-33. doi: 10.1111/j.1600-0897.2010.00932.x. Epub 2010 Dec 12. Review.

39.
40.

Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross-sectional study.

Jang JJ, Schwarcz AI, Amaez DA, Woodward M, Olin JW, Keller MJ, Schecter AD.

J Int AIDS Soc. 2010 Mar 22;13:12. doi: 10.1186/1758-2652-13-12.

41.

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC.

PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781.

42.

Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.

Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, Herold BC.

Antivir Ther. 2009;14(8):1113-24. doi: 10.3851/IMP1463.

43.

Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception.

Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC.

Am J Reprod Immunol. 2010 Feb;63(2):110-9. doi: 10.1111/j.1600-0897.2009.00768.x. Epub 2009 Dec 15. Erratum in: Am J Reprod Immunol.2010 May 1;63(5):410. Dosage error in article text.

44.

Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.

Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC.

J Infect Dis. 2009 Aug 15;200(4):599-608. doi: 10.1086/600867.

45.

Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells.

Yuan J, Liu X, Wu AW, McGonagill PW, Keller MJ, Galle CS, Meier JL.

J Virol. 2009 Jul;83(13):6391-403. doi: 10.1128/JVI.00061-09. Epub 2009 Apr 15.

46.

Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides.

Keller MJ, Herold BC.

Sex Transm Dis. 2009 Mar;36(3 Suppl):S92-5. doi: 10.1097/OLQ.0b013e318199417d. Review.

PMID:
19218889
47.

Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.

Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ.

J Virol. 2008 Jul;82(13):6576-84. doi: 10.1128/JVI.00335-08. Epub 2008 Apr 23.

48.

Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression.

Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau JM, Boivin G, Vaillant A, Herold BC.

Antivir Ther. 2007;12(8):1147-56. Erratum in: Antivir Ther. 2008;13(2):335.

PMID:
18240855
49.

HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes.

Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG.

Am J Transplant. 2008 Feb;8(2):355-65. Epub 2007 Dec 18. Erratum in: Am J Transplant.2008 May;8(5): 1081.

50.

Assessment of adherence to product dosing in a pilot microbicide study.

Hogarty K, Kasowitz A, Herold BC, Keller MJ.

Sex Transm Dis. 2007 Dec;34(12):1000-3.

PMID:
18080351

Supplemental Content

Loading ...
Support Center